ArticleCureus2025
Study of Carotid Atherosclerosis in Non-alcoholic Fatty Liver Disease Patients and Its Correlation With Serum Transaminases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as a manifestation of metabolic syndrome and a potential risk factor for cardiovascular disease (CVD). Carotid intima-media thickness (CIMT) is a validated marker of subclinical atherosclerosis which can predict the potential risk factor for CVD. This case-control study aimed to evaluate the association between NAFLD and CIMT and to investigate related metabolic and biochemical parameters. Objectives The study aimed to evaluate carotid atherosclerosis in patients with NAFLD by measuring CIMT and to determine its correlation with serum transaminase levels, specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Methodology This hospital-based case-control study included 50 patients diagnosed with NAFLD and 50 age- and sex-matched healthy controls. All participants underwent comprehensive clinical assessment, ultrasonographic grading of hepatic steatosis, CIMT evaluation via ultrasound, and laboratory investigations including liver function tests and lipid profiles. Results NAFLD was more prevalent in older adults, particularly males, and was closely associated with obesity, diabetes, and dyslipidemia. Most NAFLD cases were classified as mild (Grade I), and a significant number exhibited elevated triglycerides. The CIMT values were significantly increased in NAFLD patients across all age groups, with the most notable rise observed in individuals over 50 years of age (p<0.001). CIMT was positively associated with the severity of fatty liver and showed a significant correlation with ALT (p<0.039), but not with AST levels (p<0.327). A p-value of <0.05 was considered statistically significant. Conclusion NAFLD is associated with an increased burden of metabolic dysfunction and early vascular changes as reflected by elevated CIMT. The findings highlight a significant association between ALT levels, triglycerides, and subclinical atherosclerosis, emphasizing the need for routine cardiovascular risk stratification in patients with NAFLD, especially those aged over 50.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.